The estimated Net Worth of Robert J Bitterman is at least $58.6 Tisíc dollars as of 7 June 2024. Mr. Bitterman owns over 1,000 units of Phio Pharmaceuticals stock worth over $58,562 and over the last 9 years he sold PHIO stock worth over $0. In addition, he makes $0 as Independence Chairman of the Board at Phio Pharmaceuticals.
Robert has made over 9 trades of the Phio Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of PHIO stock worth $740 on 7 June 2024.
The largest trade he's ever made was buying 2,715 units of Phio Pharmaceuticals stock on 25 November 2022 worth over $1,140. On average, Robert trades about 761 units every 28 days since 2016. As of 7 June 2024 he still owns at least 20,990 units of Phio Pharmaceuticals stock.
You can see the complete history of Mr. Bitterman stock trades at the bottom of the page.
Robert J. Bitterman is an Independence Chairman of the Board of RXI Pharmaceuticals Corporation. Prior to joining the Company, Mr. Bitterman has served as a member and the Chairman of our Board of Directors since 2012. Prior to joining the Company, Mr. Bitterman founded Cutanea Life Sciences, Inc. in September 2005 as its President, Chief Executive Officer and Board Director. Cutanea Life Sciences, Inc. focuses on the development and commercialization of proprietary technologies to treat diseased and aging skin and was successfully acquired by Maruho Company, LTD. in February 2012, where Mr. Bitterman has continued his role as President and Chief Executive Officer. Mr. Bitterman also served as President and General Manager of Dermik Laboratories, the global dermatology strategic business unit of Aventis S.A. from 1994 to 2004. Mr. Bitterman held various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. From September 2004 until April 2005, Mr. Bitterman also held the position of President and Chief Executive Officer of Isolagen, Inc., a publicly traded bioscience technology company which developed and commercialized autologous human fibroblasts targeting soft tissue enhancement. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor of Human Letters (Honoris Causa) from the New York College of Podiatric Medicine and is a member of the Philadelphia Business Leaders Network. Based on Mr. Bitterman’s significant leadership roles in other bioscience companies, including the role of chief executive officer, his experience with development stage organizations, and his knowledge of dermatology and the pharmaceutical industry, the Nominating and Governance Committee concluded that Mr. Bitterman has the requisite experience, qualifications, attributes and skill necessary to serve as a member of the Board.
Robert Bitterman is 65, he's been the Independence Chairman of the Board of Phio Pharmaceuticals since 2013. There are 1 older and 4 younger executives at Phio Pharmaceuticals. The oldest executive at Phio Pharmaceuticals Corp. is H. Paul Dorman, 79, who is the Independent Director.
Robert's mailing address filed with the SEC is C/O PHIO PHARMACEUTICALS CORP., 11 APEX DR. SUITE 300A, PMB 2006, MARLBOROUGH, MA, 01752.
Over the last 6 years, insiders at Phio Pharmaceuticals have traded over $0 worth of Phio Pharmaceuticals stock and bought 37,351 units worth $53,368 . The most active insiders traders include Geert Cauwenbergh, Keith L Brownlie a Patricia A Bradford. On average, Phio Pharmaceuticals executives and independent directors trade stock every 82 days with the average trade being worth of $6,130. The most recent stock trade was executed by Robert J Bitterman on 7 June 2024, trading 1,000 units of PHIO stock currently worth $740.
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Phio Pharmaceuticals executives and other stock owners filed with the SEC include: